{"id":49974,"date":"2022-10-24T13:01:56","date_gmt":"2022-10-24T11:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/castle-biosciences-presents-new-data-demonstrating-the-impact-of-decisiondx-scc-test-results-on-the-management-of-medicare-eligible-patients-with-cutaneous-squamous-cell-carcinoma-and-one-or-mor\/"},"modified":"2022-10-24T13:01:56","modified_gmt":"2022-10-24T11:01:56","slug":"castle-biosciences-presents-new-data-demonstrating-the-impact-of-decisiondx-scc-test-results-on-the-management-of-medicare-eligible-patients-with-cutaneous-squamous-cell-carcinoma-and-one-or-mor","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/castle-biosciences-presents-new-data-demonstrating-the-impact-of-decisiondx-scc-test-results-on-the-management-of-medicare-eligible-patients-with-cutaneous-squamous-cell-carcinoma-and-one-or-mor\/","title":{"rendered":"Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx\u00ae-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors"},"content":{"rendered":"
\n

\nMultiple poster presentations at the 2022 Fall Clinical Dermatology Conference share this and other data supporting Castle\u2019s suite of tests for skin cancer<\/i>\n<\/p>\n

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL<\/a> #CSTL<\/a>–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from UTILISE (Clinical Utili<\/span>ty and Health Outcomes S<\/span>tudy), a prospective, multi-center, clinical utility study of DecisionDx\u00ae-SCC, designed to capture the real-world impact of DecisionDx-SCC test results on the management of patients with cutaneous squamous cell carcinoma (cSCC) and one or more risk factors. This first analysis showed that DecisionDx-SCC test results positively impacted patient management in over 80% of the patients enrolled in the study, consistent with previous clinical utility studies demonstrating that the test\u2019s results can impact risk-appropriate changes in patient management plans, within established guidelines.\n<\/p>\n

<\/a><\/p>\n

\n\u201cA true litmus test of any prognostic test is its ability to provide clinically actionable information that can drive positive change in the overall management of patients and more informed decisions than may be possible without the test\u2019s results,\u201d said Matthew S. Goldberg, M.D., board-certified dermatologist and dermatopathologist and medical director at Castle Biosciences. \u201cThe initial data from our UTILISE study highlights the potential of DecisionDx-SCC test results to prompt risk-aligned changes in treatment plans for patients with high-risk cSCC, with clinical actionability rates comparable to the impact of molecular tests currently covered by Medicare for other disease states, such as breast, prostate and lung cancer.\u201d\n<\/p>\n

\nThis data from the UTILISE study was presented during the 2022 Fall Clinical Dermatology Conference through a poster titled, \u201cA prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC).\u201d The poster can be viewed here<\/a>.\n<\/p>\n

\nIn the study, clinician recommendations for patient management are recorded before and after DecisionDx-SCC testing using standard pre-test\/post-test methodology, and any additional changes in management plans and patient outcomes are recorded every six months for three years. In this analysis of Medicare-eligible patients with high-risk cSCC (n=59), clinicians indicated that the DecisionDx-SCC test result was the most influential factor impacting their management plans for 42% of the patients. Additionally, DecisionDx-SCC test results positively impacted patient management in over 80% of patients in the cohort<\/b>, with clinicians reporting increased confidence in the recommended treatment plan (59%) and risk-aligned management changes based on the tests\u2019 results (24%). While additional analyses from UTILISE are forthcoming, the initial data from this real-world study support findings in previous clinical utility studies that DecisionDx-SCC provides valuable risk-stratification information that can guide patient management decisions and risk-appropriate treatment plan changes within established guidelines.\n<\/p>\n

\nThe following additional posters highlighting the performance of Castle\u2019s suite of tests for skin cancer were also shared during the 2022 Fall Clinical Dermatology Conference:\n<\/p>\n

\nDecisionDx\u00ae-Melanoma<\/b>\n<\/p>\n